HomeIndustriesLife Science

Life Science Industry Assurance

Scope: Pharma · CROs · Medical Devices · Biotechnology · Life Science Software · Laboratories · R&D
Get a Proposal → Book Discovery Call
The Risks Organisations Can No Longer Ignore

Risks facing life science organisations

Industry-specific risks are shown first, followed by risks common to all sectors.

Industry Specific
GxP Regulatory Exposure

GMP, GCP, GLP, GDP, and GVP obligations create significant inspection risk. Health authority actions including FDA warning letters, EMA findings, MHRA failures, import alerts, product recalls, and licence suspension can create severe consequences for unprepared organisations.

Industry Specific
AI, Software & Validation Compliance

Evolving expectations under EU GMP Annex 11 / Annex 22, the EU AI Act, FDA software assurance principles, and CSV requirements create regulatory exposure where AI systems and digital processes are not effectively governed or validated.

Industry Specific
Data Integrity & Privacy Risk

Weak ALCOA+ controls, poor audit trail governance, inadequate access management, and GDPR/privacy obligations can lead to regulatory findings, enforcement action, and reduced confidence in clinical, laboratory, or manufacturing data.

Common Risk
Customer & Supply Chain Readiness

Customers, investors, and supply chain partners increasingly require certifications, audit outcomes, and evidence of control maturity before awarding or renewing business.

Common Risk
Regulatory Exposure

Evolving regulations, intensified oversight, and sector-specific obligations create risk of non-compliance, penalties, disruption, and reputational damage.

Common Risk
Business Continuity & Disaster Recovery

Absence of tested business continuity plans and disaster recovery capabilities leaves organisations vulnerable to operational disruption, customer impact, and regulatory non-compliance.

Common Risk
Cyber Security & Data Trust Risks

Cyber threats, ransomware, privacy obligations, and data governance failures can directly impact operations, customer confidence, and regulatory standing.

Common Risk
Certification Readiness Gaps

Poor preparation can lead to delayed certifications, major nonconformities, suspended approvals, and missed commercial opportunities.

Our Approach

How AjaCertX works with you

A structured six-step methodology — from initial assessment through to ongoing governance and continual improvement.

Step 01
Assess

We assess your current GxP compliance posture, quality management system and regulatory readiness against FDA, EMA, MHRA and TGA expectations, identifying all gaps with a prioritised action plan.

Step 02
Implement

Our specialists work alongside your team to design, document and embed the required processes, procedures, records and controls.

Step 03
Train

We build internal capability through GxP awareness, GAMP 5, data integrity and lead auditor training — equipping your people to own and sustain the quality system.

Step 04
Audit

Rigorous internal audits and pre-certification mock assessments verify conformity and ensure your organisation is fully prepared for third-party assessment.

Step 05
Certify

We support liaison with your chosen certification body, manage the audit process and drive first-time certification success.

Step 06
Govern

Ongoing support through surveillance audits, recertification, continual improvement and management review — sustaining conformity and driving performance.

Ready to strengthen your life science compliance programme?

Speak to a life science compliance specialist. Detailed proposal within 48 hours.

WhatsApp Connect